Gefitinib
Gefitinib is an EGFR tyrosine kinase inhibitor used in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC).
Gefitinib is an EGFR tyrosine kinase inhibitor used in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). By inhibiting EGFR signaling, it can suppress downstream proliferative and survival pathways that drive tumor growth in susceptible cancers. Its clinical role is most established in molecularly selected NSCLC, where EGFR dependence makes tumors more responsive to EGFR-targeted therapy.
In recent biomedical research, gefitinib has also served as a model drug for studying acquired resistance to EGFR-TKIs. Investigators have used gefitinib-resistant cell and tumor systems to examine compensatory signaling networks, including Protein kinase B (PKB)/P70S6K, Wnt/β-catenin pathway activity, STING1-associated immune signaling, and ferroptosis-related regulators such as GPX4 and SLC7A11/xCT. These studies reflect the broader challenge that, although gefitinib can be effective initially, resistance frequently limits durable benefit in NSCLC.
Where the papers sit
9 papers from the last 6 months study gefitinib directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 1 observational · 2 human data · 5 preclinical · 1 unclassified
Themes one subject
Those 9 are all about one subject.
-
EGFR-Targeted Drug Research
EGFR-targeted drug research spans gefitinib efficacy, resistance, delivery, toxicity and next-generation inhibitor design. Cancer studies connect PI3K/AKT, MAPK/RAF1 and apoptosis with activity in lung, colorectal, breast and liver models. CAMK2D-driven AKT phosphorylation highlights resistance, while antibody and aptamer endocytosis offers a delivery strategy. Neurotoxicity, pharmacovigilance and multitarget AChE/EGFR compounds broaden the safety and drug-development agenda.
Papers
The 9 papers from the last 6 months that study gefitinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
EGFR-Targeted Drug Research (9)
- Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
- Unveiling the potential mechanisms of gefitinib-induced neurotoxicity: A network toxicology approach. Computational biology and chemistry · 16 Jul 2026 PMID 42462354
- Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K/AKT and MAPK/RAF1/c-FOS pathways. Molecular biology reports · 16 Jul 2026 PMID 42461339
- Exploring gefitinib to enhance endocytosis of antibodies and nucleic acid aptamers targeting EGFR in glioblastoma. Nanoscale · 2 Jul 2026 PMID 42390764
- Hedyotis diffusa injection suppresses breast cancer progression and lung metastasis through dual targeting of PTK2B and CCN2. Phytomedicine : international journal of phytotherapy and phytopharmacology · 2 Jun 2026 PMID 42229377
- A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. Medicine · 23 May 2026 PMID 42175505
- Development of dual A2AR/EGFR targeting pyrazoline-thiazole hybrids for restored apoptotic balance in colorectal cancer. Bioorganic chemistry · 19 May 2026 PMID 42155202
- CAMK2D isoform 15 facilitates gefitinib resistance via AKT phosphorylation in lung adenocarcinoma. Cancer biology & medicine · 19 May 2026 PMID 42152470
- Development of tacrine-based multitarget-directed ligands as dual AChE/EGFR inhibitors with neuroprotective activity. Bioorganic & medicinal chemistry · 10 May 2026 PMID 42107267
By study type
Observational studies and case reports (1)
- Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
Human data, design not indexed (2)
- Unveiling the potential mechanisms of gefitinib-induced neurotoxicity: A network toxicology approach. Computational biology and chemistry · 16 Jul 2026 PMID 42462354
- A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. Medicine · 23 May 2026 PMID 42175505
Preclinical: animal, cell and lab studies (5)
- Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K/AKT and MAPK/RAF1/c-FOS pathways. Molecular biology reports · 16 Jul 2026 PMID 42461339
- Exploring gefitinib to enhance endocytosis of antibodies and nucleic acid aptamers targeting EGFR in glioblastoma. Nanoscale · 2 Jul 2026 PMID 42390764
- Hedyotis diffusa injection suppresses breast cancer progression and lung metastasis through dual targeting of PTK2B and CCN2. Phytomedicine : international journal of phytotherapy and phytopharmacology · 2 Jun 2026 PMID 42229377
- Development of dual A2AR/EGFR targeting pyrazoline-thiazole hybrids for restored apoptotic balance in colorectal cancer. Bioorganic chemistry · 19 May 2026 PMID 42155202
- Development of tacrine-based multitarget-directed ligands as dual AChE/EGFR inhibitors with neuroprotective activity. Bioorganic & medicinal chemistry · 10 May 2026 PMID 42107267
Unclassified: not yet indexed with MeSH (1)
- CAMK2D isoform 15 facilitates gefitinib resistance via AKT phosphorylation in lung adenocarcinoma. Cancer biology & medicine · 19 May 2026 PMID 42152470
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-04 by GPT. Drafted by language models from published abstracts; not medical advice.